Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 7, 2009 | Post-IPO Equity | $43.50M | 1 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Caxton Advantage Life Sciences Fund
|
— | Post-IPO Equity |